ALDX Aldeyra Therapeutics, Inc.

4.35
-1  -16%
Previous Close 5.20
Open 5.50
Price To book 3.02
Market Cap 27.17M
Shares 6,245,000
Volume 1,832,901
Short Ratio 1.73
Av. Daily Volume 74,598

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated 2Q 2017.
ADX-102
Dry eye syndrome
Phase 2b enrollment initiation announced February 7, 2017. Data due 2H 2017.
ADX-102
Allergic conjunctivitis
Phase 3 to begin 2Q 2017 with data due late 2018.
ADX-102
Noninfectious anterior uveitis
Phase 2 data released August 2016. Phase 3 trial to be initiated 2H 2017 with data due in 2019.
ADX-102
Sjögren-Larsson Syndrome (SLS)

Latest News

  1. Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
  2. Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
  3. Aldeyra Therapeutics Reports Full Year 2016 Financial Results
  4. Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
  5. Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
  6. Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading
  7. Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome
  8. Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
  9. Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock
  10. Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock
  11. Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
  12. Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day
  13. Aldeyra Therapeutics Announces Clinical Development Update for Phase 3 Programs
  14. Is Carolina Bank Holding Inc. (NC) (CLBH) A Good Stock To Buy?
  15. Aldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016
  16. Aldeyra Therapeutics (ALDX) is Oversold: Can It Recover?
  17. Aldeyra Therapeutics, Inc. :ALDX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 21, 2016
  18. Aldeyra Therapeutics (ALDX) Worth a Look: Stock Gains 7%
  19. Aldeyra Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update